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UK and 5) Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, ThailandAbstractStaphylococcus aureus bacteraemia (SAB) is a common, serious infection that is associated with high rates of morbidity and mortality. Evidence
suggests that infectious disease consultation (IDC) improves clinical management in patients with SAB. We examined whether the
introduction of a routine bedside IDC service for adults with SAB improved clinical management and outcomes compared to telephone
consultation. We conducted an observational cohort study of 571 adults with SAB at a teaching hospital in the United Kingdom between
July 2006 and December 2012. A telephone consultation was provided on the day of positive blood culture in all cases, but an additional
bedside IDC was provided after November 2009 (routine IDC group). Compared to patients in the pre-IDC group, those in the routine
IDC group were more likely to have a removable focus of infection identiﬁed, echocardiography performed and follow-up blood cultures
performed. They also received longer courses of antimicrobial therapy, were more likely to receive combination antimicrobial therapy
and were more likely to have SAB recorded in the hospital discharge summary. There was a trend towards lower mortality at 30 days in
the routine IDC group compared to the pre-IDC group (12% vs. 22%, p 0.07). Our ﬁndings suggest that routine bedside IDC should
become the standard of care for adults with SAB.
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E-mail: et317@cam.ac.ukIntroductionStaphylococcus aureus bacteraemia (SAB) is a common, serious
infection with mortality rates of up to 40% [1–3]. Several
retrospective studies have shown improvements in the clinical
management and outcome of patients with bacteraemia who
receive infectious diseases specialist advice. Infectious diseaseClinical Microbiology and Infection © 2015 The Authors. Published by El
This is an ospecialist advice for patients with bacteraemia increases the
prescription of correct empirical therapy [4–7] and results in a
narrowing of the spectrum of antimicrobial therapy [5]. In
patients with SAB, infectious disease consultation (IDC) leads
to improvements in clinical management [8–11], is associated
with lower rates of recurrent disease [8,9], is associated with
reductions in mortality [11,12] and is cost effective [13,14].
One study has also compared telephone consultation with
bedside IDC in the management of SAB [15]. A recent review
article has recommended that all adult patients with SAB should
undergo echocardiography [16].
In the United Kingdom, the management of SAB varies
widely between different hospitals. When blood cultures
become positive, clinical microbiologists usually provideClin Microbiol Infect 2015; 21: 779–785
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clinical review is not routine clinical practice, and often only
occurs in centres with infectious diseases services. The aim of
this study was to evaluate whether the introduction of routine
bedside IDC service for adults with SAB resulted in improve-
ments in management and outcomes compared to telephone
consultation.Patients and methodsStudy setting and participants
An observational cohort study of adults with SAB was
conducted at the Cambridge University Hospitals National
Health Service Foundation Trust (CUHNHFT), a tertiary-care
referral centre. All ﬁrst episodes of SAB in patients older
than 18 years admitted between July 2006 and December 2012
were eligible for inclusion in the study. The exclusion criteria
included death before blood cultures becoming positive,
transfer to another hospital before the blood cultures became
positive, polymicrobial cultures or positive cultures that were
deemed to be contaminated.
Study procedures
On the day the blood culture became positive, the clinical
microbiologist provided telephone advice to the primary clinical
team. Before November 2009, patients were not routinely
reviewed by the infectious diseases service; an IDC only
occurred if requested by the primary clinical team, and this
usually consisted of a single bedside review. For patients
admitted between July 2006 and November 2009 (the pre-IDC
group), data were collected retrospectively from the medical
records and a national register of deaths. In November 2009, a
routine bedside IDC service was introduced for all patients
with SAB. In addition to the telephone advice provided by the
microbiology team, patients received an initial bedside clinical
review, followed by weekly clinical review by the IDC team
until the time of hospital discharge. Written recommendations
for investigation and management were recorded in the medical
records. Data in this group were collected prospectively.
Study deﬁnitions and outcome measures
Previously deﬁned criteria were used to determine if the
source of the bacteraemia was due to soft tissue infection [8],
intravascular (iv) catheter infection [17], native and prosthetic
valve infective endocarditis [18] or bone and joint infections
(US Centers for Disease Control and Prevention, http://www.
cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf).
For all other foci of infection, clinical and/or radiologic and/or
microbiologic evidence was used to determine the source ofClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4infection. Community-acquired, hospital-acquired and
healthcare-associated infections were deﬁned according to
previously published criteria [19]. Uncomplicated SAB was
deﬁned as negative blood culture results 2 to 4 days after the
initial positive blood culture ﬁnding and/or defervescence at 72
hours, and no evidence of endocarditis, metastatic disease or
deep focus of infection [20]. Complicated SAB cases did not
meet the criteria for uncomplicated infection, had an unknown
focus or died within 72 hours. Recurrence was deﬁned as
blood cultures positive for S. aureus 14 days after the initial
positive result. Metastatic infection was deﬁned as a secondary
site of infection distant from the primary site of infection.
Appropriate antimicrobial therapy was deﬁned as therapy to
which the isolate was determined susceptible by antimicrobial
susceptibility testing. β-Lactam therapy was recommended for
methicillin-susceptible SAB, and vancomycin was recom-
mended for methicillin-resistant SAB unless the patient had a
contraindication to this. The duration of therapy was the length
of time in days that the patient received antibiotics to which
the isolate was susceptible, and was measured from the time
when the blood culture result became available. Patients who
died while receiving antibiotic therapy were excluded from the
analyses of antibiotic duration. Combination antibiotic therapy
was prescribed for certain infections including infective
endocarditis, and bone and joint infections [21–23].
The presence of comorbidities was assessed using the
Charlson comorbidity index (CCI) and were dichotomized into
scores of <3 or 3 [24,25]. Immunosuppressive therapy
included corticosteroid therapy administered at a minimum
dose equivalent to 5 mg prednisone for a minimum period of 2
weeks, neutropenia from any cause, treatment with antineo-
plastic therapy or a biologic agent or patients undergoing
plasmapheresis. Chronic skin conditions were deﬁned as those
conditions that predisposed the subject to colonization with
S. aureus.
Evidence from previous studies was used to determine
quality indicators for the investigation and management of SAB.
These included: (a) identiﬁcation and removal of a removable
focus of infection [8,26]; (b) performing repeat blood cultures
at 48 to 96 hours [27]; (c) performing an echocardiogram
[27,28]; (d) use of β-lactam therapy for methicillin-susceptible
SAB [29,30]; (e) treatment of uncomplicated infection with
14 days of iv antibiotics [26]; and (f) treatment of complicated
infection with a minimum of 28 days of iv antibiotics [22,26].
We also noted whether the SAB was recorded in the hospital
discharge summary.
The following outcome measures were assessed: (a) defer-
vescence within 72 hours; (b) duration of hospital stay; (c)
death at 30 and 90 days after ﬁrst positive blood culture; and [4]
recurrent SAB at 30 and 90 days after ﬁrst positive bloodEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 779–785
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and signs consistent with SAB at the time of death, if there was
a persistent focus of S. aureus infection at the time of death and/
or if the blood culture was positive at the time of death.
Statistical methods
Data were analysed by Stata, version 12 (StataCorp, USA).
Continuous variables were reported as median and inter-
quartile range, and categorical variables reported as number
and percentage. The Fisher exact test was used to compare
categorical variables and the Mann-Whitney test to compare
continuous variables. Time-to-event outcomes were analysed
by Kaplan-Meier survival analysis and the Cox proportional
hazard model. A multivariable Cox proportional hazard model,
adjusted for age, sex, hospital-acquired infection, methicillin-
resistant S. aureus (MRSA) and CCI, was used to compare the
30- and 90-day mortality between the two groups.FIG. 1. Flow chart of study participants.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an oEthics statement
The study was approved by the University of Cambridge Hu-
man Biology Research Ethics Committee (reference
HBREC.2013.05) and by the CUHNHFT Research and Devel-
opment Department (reference A092869).ResultsBaseline characteristics
A total of 571 adults with SAB between 16 July 2006 and 31
December 2012 were eligible for inclusion in the study. Ninety-
four subjects were excluded for various reasons, leaving 477 in
the ﬁnal analysis (Fig. 1). There were 294 adults in the pre-IDC
group (60 of whom received a bedside IDC requested by the
primary clinical team) and 183 patients in the routine IDC
group (178 of whom received an IDC). Of the ﬁve patients whoof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 779–785
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
TABLE 2. Clinical features of infection in adults with
Staphylococcus aureus bacteraemia
Characteristic
All patients
(N [ 477), n
(%)
Before IDC
(n [ 294), n
(%)
Routine IDC
(n [ 183), n
(%) p
Acquisition of
infection
Community
acquired
131 (27.5) 67 (22.8) 64 (35.0) 0.004
Healthcare
associated
129 (27.0) 75 (25.5) 54 (29.5) 0.34
Hospital acquired 217 (45.5) 152 (51.7) 65 (35.5) <0.001
MRSA 127 (26.6) 101 (34.4) 26 (14.2) <0.001
Focus of infection
Unknown 65 (13.6) 48 (16.3) 17 (9.3) 0.04
Central venous
catheter
110 (23.1) 70 (23.8) 40 (21.9) 0.66
Peripheral venous
catheter
39 (8.2) 24 (8.2) 15 (8.2) 1.0
Thrombophlebitis 35 (7.3) 12 (4.1) 23 (12.6) 0.001
Implanted
vascular device
4 (0.84) 0 (0) 4 (2.2) 0.02
Infective
endocarditis
26 (5.5) 12 (4.1) 14 (7.7) 0.10
Native valve 18 (3.8) 8 (2.7) 10 (5.5) 0.14
Prosthetic valve 8 (1.7) 4 (1.4) 4 (2.2) 0.5
Joint infection 45 (9.4) 21 (7.1) 24 (13.1) 0.04
Native joint 24 (5.0) 11 (3.7) 13 (7.1) 0.13
Prosthetic joint 21 (4.4) 10 (3.4) 11 (6.0) 0.25
Vertebral
osteomyelitis
33 (6.9) 17 (5.8) 16 (8.7) 0.27
Epidural abscess 23 (4.8) 13 (4.4) 10 (5.5) 0.66
Osteomyelitis
(nonvertebral)
24 (5.0) 10 (3.4) 14 (7.7) 0.05
Skin and soft
tissue infection
147 (30.8) 81 (27.6) 66 (36.1) 0.05
Deep tissue
abscess
24 (5.0) 18 (6.1) 6 (3.3) 0.20
Lung 40 (8.4) 32 (10.9) 8 (4.4) 0.02
Urogenital 22 (4.6) 15 (5.1) 7 (3.8) 0.66
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patient was transferred to another hospital before IDC and one
patient was discharged from hospital after 1 day and completed
treatment in the community. The baseline characteristics of the
two groups were similar for most criteria (Table 1). The pro-
portion of patients with prosthetic material was higher in the
routine IDC group compared to the pre-IDC group (55% vs.
44%, p 0.02). The proportion of patients who had a CCI score
of 3 was higher in the pre-IDC group compared to the
routine IDC group (48% vs. 38%, p 0.03).
Clinical features of SAB
Overall, 46% of SAB cases were hospital acquired, 27% were
healthcare associated and 28% were community acquired
(Table 2). The frequency of hospital-acquired SAB was higher in
the pre-IDC group (52% vs. 36%, p < 0.001), as was the fre-
quency of MRSA compared to methicillin-susceptible S. aureus
bacteraemia (34% vs. 14%, p < 0.001). The most common foci
of infection were skin and soft tissue infections (31%), central
venous catheters (23%) or unknown foci (14%) (Table 2). The
proportion of patients with an unknown focus was higher in the
pre-IDC group (16% vs. 9%, p 0.04). Certain foci of infection
(e.g. thrombophlebitis, implanted vascular device, joint infec-
tion, nonvertebral osteomyelitis, skin and soft tissue infections)TABLE 1. Baseline characteristics of adults with
Staphylococcus aureus bacteraemia
Characteristic
All patients
(N [ 477)
Before IDC
(n [ 294)
Routine IDC
(n [ 183) p
Age (years) 65.6
(50.4–76.4)
65.8
(50.5–77.4)
64.8
(50.2–75.3)
0.47
Male sex 287 (60.2) 184 (62.6) 103 (56.3) 0.18
Duration of bacteraemia
symptoms before
treatment
0.005
0–24 hours 220 (46.1) 152 (51.7) 68 (37.2)
25–72 hours 80 (16.8) 38 (12.9) 42 (23.0)
>73 hours 141 (29.6) 85 (28.9) 56 (30.6)
Unknown 36 (7.6) 19 (6.5) 17 (9.3)
Surgery in last 30 days 93 (19.5) 65 (22.1) 28 (15.3) 0.08
Comorbidity/risk factor
Diabetes mellitus 104 (21.8) 55 (18.7) 49 (26.8) 0.04
Cardiac failure 50 (10.5) 31 (10.5) 19 (10.4) 1.00
Ischaemic heart disease 75 (15.7) 49 (16.7) 26 (14.2) 0.52
Peripheral vascular disease 36 (7.6) 22 (7.5) 14 (7.7) 1.00
Cerebrovascular disease 66 (13.8) 46 (15.7) 20 (10.9) 0.17
Chronic pulmonary disease 93 (19.5) 64 (21.8) 29 (15.9) 0.12
Liver disease 65 (13.6) 41 (14.0) 24 (13.1) 0.89
Malignancy 110 (23.1) 72 (24.5) 38 (20.8) 0.37
Organ transplant 22 (4.6) 9 (3.1) 13 (7.1) 0.05
HIV infection 3 (0.63) 2 (0.7) 1 (0.6) 1.00
Intravenous drug abuse 26 (5.5) 12 (4.1) 14 (7.7) 0.10
Immunosuppression 115 (24.1) 62 (21.1) 53 (29.0) 0.06
Moderate to severe renal
disease
96 (20.1) 63 (21.4) 33 (18.0) 0.48
Chronic skin condition 86 (18.0) 41 (14.0) 45 (24.6) 0.005
Prosthetic material 229 (48.0) 129 (43.9) 100 (54.6) 0.02
Charlson comorbidity index 2 (1–4) 2 (1–5) 2 (1–4) 0.02
Score 3 210 (44.0) 141 (48.0) 69 (37.7) 0.03
Data are presented as median (interquartile range) or n (%).
IDC, infectious disease consultation.
Central nervous
system
11 (2.3) 5 (1.7) 6 (3.3) 0.35
Mediastinitis 5 (1.1) 2 (0.68) 3 (1.6) 0.38
Other 10 (2.1) 6 (2.0) 4 (2.2) 1.0
Complicated
infection
371 (77.8) 224 (76.2) 147 (80.3) 0.31
Metastatic infection
At presentation 33 (6.9) 21 (7.1) 12 (6.6) 0.86
Ever occurred 58 (12.2) 33 (11.2) 25 (13.7) 0.47
IDC, infectious disease consultation.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4were more frequently identiﬁed in the routine IDC group
compared to the pre-IDC group (Table 2). The frequency of
uncomplicated infection was similar in each group (24% vs. 20%,
p 0.31).
Quality indicators for management of SAB
The median time to receive an IDC was shorter in the routine
IDC group (2 vs. 3 days, p < 0.001) (Table 3). A repeat blood
culture was performed more frequently in the routine IDC
group (93% vs. 65%, p < 0.001). A removable focus of infection
was more frequently identiﬁed in the routine IDC group (49%
vs. 40%, p 0.05), although there was no signiﬁcant difference in
the proportion of patients who had the focus removed. Echo-
cardiography was performed more frequently in the routine
IDC group (91% vs. 38%, p < 0.001). Combination antibiotic
therapy was prescribed more frequently in the routine IDC
group (24% vs. 16%, p 0.04). There was no difference in the useEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 779–785
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TABLE 3. Quality indicators and outcomes in the
management of Staphylococcus aureus bacteraemia
Characteristic
All patients
(N [ 477)
Before IDC
(n [ 294)
Routine IDC
(n [ 183) p
Quality Indicators
IDC
Bedside IDC 238 (49.9) 60 (20.4) 178 (97.3) <0.001
Telephone-only
consultation
239 (50.1) 234 (79.6) 5 (2) <0.001
Time to bedside
IDC (days)
2 (1–3) 3 (1–9) 2 (1–3) <0.001
Repeat blood culture
performed
361 (75.7) 191 (65.0) 170 (92.9) <0.001
Removable focus of
infection
205 (43.0) 116 (39.5) 89 (48.6) 0.06
Focus of infection
removed
190 (92.7) 108 (93.1) 82 (92.1) 0.79
Echocardiogram
First
echocardiogram
performed
279 (58.5) 113 (38.4) 166 (90.7) <0.001
TTE 273 (95.1) 114 (98.3) 159 (93.0) 0.25
TOE 14 (4.9) 2 (1.7) 12 (7.0) <0.001
Days to
echocardiogram
7 (4–10) 7 (4–12) 7 (4–9) 0.54
Subsequent
echocardiogram
40 (8.3) 9 (3.1) 31 (16.9) <0.001
TTE 24 2 22 <0.001
TOE 16 7 9 0.19
Antibiotic therapy
Duration of iv therapy
(days)a
19.5 (13–31) 15 (10–28) 29 (17 -42) <0.001
Complicated
infection
22 (13–35) 16 (10–29) 29 (18–45) <0.001
Uncomplicated
infection
16 (11–21) 14.5 (10–19) 21 (15–30) <0.001
Duration total
therapy (days) 3
28 (16–42) 21 (14 - 32) 31 (20–48) <0.001
Complicated
infection
29 (17–45) 24 (14–41) 34 (28–53) <0.001
Uncomplicated
infection
19 (15–29) 18 (14–29) 22 (16–30) 0.07
β-Lactam therapy
for MSSAb
310/349 (71.9) 170/193 (88.1) 140/156 (89.7) 0.73
Combination
antibiotic therapy
92 (19.3) 48 (16.3) 44 (24.0) 0.04
SAB recorded in
discharge summary
259 (54.3) 121 (41.2) 138 (75.4) <0.001
Outcome Measures
Defervescence within
72 hours
293/442 (66.3) 185/271 (68.3) 108/171 (63.2) 0.30
Length of hospital stay
(days)c
29 (17–52) 30 (16–51) 29 (17–53) 0.89
Mortality
30 day 86 (18) 64 (21.9) 22 (12) 0.007
90 day 128 (26.8) 89 (30.3) 39 (21.3) 0.03
Death attributed to
SAB
59/128 (46.0) 50/89 (56.2) 9/39 (23.1) <0.001
Recurrent disease
30 day 4 (0.84) 4 (1.4) 0 (0) 0.30
90 day 16 (3.4) 12 (4.1) 4 (2.2) 0.31
Data are presented as median (interquartile range) or n (%).
IDC, infectious disease consultation; iv, intravenous; MSSA, methicillin-susceptible
S. aureus; SAB, S. aureus bacteraemia; TOE, transoesophageal echocardiogram; TTE,
transthoracic echocardiogram.
aCalculation excluded patients who died while receiving active treatment with
antibiotic therapy.
bCalculation based on patients with MSSA.
cCalculation excluded patients who died in hospital.
TABLE 4. Factors associated with 30- and 90-day mortality
Factor
Univariable model Multivariable model
Crude hazard
ratio (95% CI) p
Adjusted hazard
ratio (95% CI) p
30-day mortality
IDC 0.51 (0.32–0.83) 0.007 0.62 (0.37–1.04) 0.07
Age 1.03 (1.02–1.05) <0.001 1.03 (1.02–1.05) <0.001
Male sex 0.90 (0.58–1.39) 0.63 1.00 (0.64–1.58) 0.97
Hospital-
acquired
infection
1.15 (0.76–1.76) 0.51 0.88 (0.56–1.38) 0.57
MRSA 1.98 (1.29–3.05) 0.003 1.55 (0.98–2.45) 0.06
CCI score >3 2.88 (1.83–4.52) <0.001 2.42 (1.52–3.85) <0.001
90-day mortality
IDC 0.65 (0.44–0.94) 0.02 0.85 (0.57–1.28) 0.44
Age 1.04 (1.03–1.05) <0.001 1.04 (1.02–1.05) <0.001
Male sex 0.97 (0.68–1.38) 0.85 1.06 (0.74–1.53) 0.76
Hospital-
acquired
infection
1.49 (1.05–2.11) 0.03 1.20 (0.82–1.74) 0.35
MRSA 2.01 (1.41–2.87) <0.001 1.56 (1.07–2.29) 0.02
CCI score >3 3.40 (2.33–4.96) <0.001 2.89 (1.96–4.25) <0.001
CCI, Charleston comorbidity index; CI, conﬁdence interval; IDC, infectious disease
consultation; MRSA, methicillin-resistant S. aureus.
FIG. 2. Kaplan-Meier survival estimate for adults with SAB.
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two groups.
The median duration of antibiotic therapy was 19.5 days for
iv therapy and 28 days for the total duration of therapy (iv and
oral). The duration of therapy was longer in the routine IDC
group, both for iv antibiotic therapy (29 vs. 15 days, p < 0.001)
and for total duration of therapy (31 vs. 21 days, p < 0.001).Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an oThe duration of treatment for both uncomplicated and
complicated infection was longer in the routine IDC group. For
uncomplicated infections, the duration of iv antibiotic therapy
(21 vs. 14.5 days, p < 0.001) and total antibiotic therapy (22 vs.
18 days, p 0.07) was longer in the routine IDC group compared
to the pre-IDC group. For complicated infections, the duration
of iv antibiotic therapy (29 vs. 16 days, p < 0.001) and total
antibiotic therapy (34 vs. 24 days, p < 0.001) was also longer in
the routine IDC group than the pre-IDC group. SAB was more
frequently recorded in the discharge summary in the routine
IDC group (75% vs. 41%, p < 0.001).
Outcome from SAB
Length of hospital stay and defervescence within 72 hours
were similar between groups (Table 3). In univariable analyses,
mortality at 30 and 90 days was lower in the routine IDC
group (Table 4 and Fig. 2). In a multivariable Cox proportionalof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 779–785
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
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MRSA infection and CCI, we found that there was a trend
towards lower mortality at 30 days in the routine IDC group
(12% vs. 22%, hazard ratio 0.62, 95% conﬁdence interval
0.37–1.03, p 0.07) and at 90 days (21% vs. 30%, hazard ratio
0.85, 95%, conﬁdence interval 0.57–1.28, p 0.44). Older age
and higher CCI scores were associated with a higher mortality
at 30 days. Increased age, MRSA infection and CCI scores
were associated with 90-day mortality. Death was attributed
to SAB in a higher proportion in the pre-IDC group (56% vs.
23%, p < 0.001). There was no signiﬁcant difference in
recurrent SAB between the two groups.DiscussionOur study ﬁndings support the use of routine bedside IDC for
the management of adults with SAB and conﬁrmed that a
bedside IDC is superior to telephone consultation [15]. Patients
in the routine IDC group were more likely to have a removable
focus of infection identiﬁed, echocardiography performed and
follow-up blood cultures performed. They received longer
courses of antimicrobial therapy, were more likely to be
receive combination antimicrobial therapy and were more
likely to have SAB recorded in the hospital discharge summary.
In contrast to previous studies, we provided an initial clinical
review followed by weekly inpatient follow-up until the time of
hospital discharge. This enabled us to provide ongoing clinical
advice and to monitor compliance with our recommendations.
Patients in the routine IDC group received longer courses of
antibiotic therapy for both complicated and uncomplicated in-
fections. Patients in the routine IDC group received 4 to 6
weeks of iv antimicrobial therapy for complicated infection, in
accordance with current treatment recommendations. This
was an improvement compared to the pre-IDC group. In
uncomplicated infection, however, there was a tendency to
treat patients for longer than 14 days of iv therapy. This was an
unexpected ﬁnding and suggests that although these patients
fulﬁlled the study-deﬁned criteria for uncomplicated infection, a
longer treatment course was administered. Possible explana-
tions include the attending infectious disease specialist recom-
mending a longer course of therapy on the basis of subsequent
data (e.g. evolving clinical features, failure to respond to treat-
ment) or the primary clinical care team deferring the decision
to stop antimicrobial therapy until the patient received his or
her weekly review by the IDC team.
The frequency of hospital-acquired bacteraemia was lower in
the routine IDC group. This may be explained by a decline in
MRSA bacteraemia after the introduction of infection control
measures (MRSA screening and decolonization of inpatients), asClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4well as the introduction of a vascular catheter insertion service
at our hospital during the study period.
Inpatient mortality and death at 30 and 90 days were higher
in the pre-IDC group. These ﬁndings may have been related to
improvements in clinical management or changes in risk factors
over time. A higher proportion of patients in the pre-IDC
group had MRSA bacteraemia and a CCI score of 3, sug-
gesting the pre-IDC group was a more unwell cohort. None-
theless, there was a trend towards reduced mortality in
multivariable analysis in the routine IDC group. This may have
been related to a decrease in the proportion of patients with an
unknown focus, which is known to be associated with increased
mortality. Fewer deaths were attributed to SAB in the routine
group, which may reﬂect improved clinical management during
this period.
We acknowledge several limitations to our study. We aimed
to minimize selection bias by including all adults with SAB and
collecting data using a standard case record form. However,
data from the pre-IDC group were collected retrospectively
from existing documentation, which may not have been as
comprehensive as that recorded prospectively by the IDC team.
The time period of the study (2006–2009 for the pre-IDC
group and 2009–2012 for the routine IDC group) may have
been associated with confounding factors such as introduction
of clinical services (e.g. vascular catheter insertion service).
Nevertheless, our ﬁndings suggest that routine regular bedside
IDC is superior to a telephone consultation for the manage-
ment of SAB in adults and should become the standard of care.Transparency declarationThis study was funded by grants from the United Kingdom
Clinical Research Collaboration (UKCRC) Translational
Research Initiative (Medical Research Council – MRC grant
G1000803), the Hospital Infection Society and the National
Institute of Health Research (NIHR) Cambridge Biomedical
Research Centre. MET is a Clinician Scientist Fellow funded by
the Academy of Medical Sciences and the Health Foundation. All
authors report no conﬂicts of interest relevant to this article.
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